Last reviewed · How we verify

NCT06709729

Switch of AndroidAPS to Commercially Available AID Systems

Active, enrolled NA Last updated 29 November 2024
What this trial tests

NA trial testing Insulin pump with closed-loop system in Diabetes Mellitus, Type 1 in 41 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 December 2020
Primary endpoint
1 December 2024
31 December 2024

Quick facts

Lead sponsorCharles University, Czech Republic
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsequential
Maskingnone
Primary purposetreatment
Enrollment41
Start date1 December 2020
Primary completion1 December 2024
Estimated completion31 December 2024
Sites1 location across Czechia

Drugs / interventions tested

Conditions studied

Sponsor

Charles University, Czech Republic

Who can join

18 and older, any sex, with Diabetes Mellitus, Type 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study was to investigate the switch between open-source automated insulin delivery system (OS-AID) - AndroidAPS (AAPS) and commercially available AID systems - Control-IQ (CIQ) and MiniMed 780G (780G) in extended follow-up study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 1

Currently open trials in the same condition.

Other Charles University, Czech Republic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06709729.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing